Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101, Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480.
While PT-141 works as the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101, Semaglutide is a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480.
PT-141
POMC
Semaglutide
GCG
PT-141 and Semaglutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: PT-141 is more often discussed in the realm of Reproductive health, whereas Semaglutide is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. They also influence different molecular systems, with PT-141 tracking more closely to GPCR receptor while Semaglutide centers more on GLP-1 receptor. Both are synthetic in origin. PT-141 takes the form of a cyclic peptide, whereas Semaglutide is closer to a peptide conjugate, PT-141 carries acetylation features, while Semaglutide instead reflects lipidation changes; while their sequence patterns also diverge, with PT-141 showing protein-mimetic sequence features and Semaglutide showing alpha-helical domain features.